Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Turkish Journal of Biochemistry

Türk Biyokimya Dergisi


IMPACT FACTOR 2018: 0.329

CiteScore 2018: 0.28

SCImago Journal Rank (SJR) 2018: 0.138
Source Normalized Impact per Paper (SNIP) 2018: 0.169

Online
ISSN
1303-829X
See all formats and pricing
More options …
Volume 41, Issue 6

Issues

Gilbert’s syndrome: protective effect on endothelial dysfunction

Gilbert Sendromu: Endotel Disfonksiyonu Üzerinde Koruyucu Etkisi

Erdim Sertoğlu
  • Corresponding author
  • GATA Haydarpasa Training Hospital, Department of Medical Biochemistry, İstanbul, Turkey, Tel.: +90 312 304 2000
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Serkan Tapan
  • Yuksek Ihtisas University School of Medicine, Department of Medical Biochemistry, Ankara, Turkey
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Teoman Doğru / Ramazan Acar / Tolga Doğan / Selami İnce / Cumhur Bilgi
Published Online: 2016-10-14 | DOI: https://doi.org/10.1515/tjb-2016-0150

Abstract

Objective:

Gilbert’s syndrome (GS), is a benign condition characterized by unconjugated hyperbilirubinemia related to a decreased hepatic glucuronidating activity without symptoms and signs of liver disease or overt hemolysis. In the present study, we aimed to assess circulating levels of asymmetric dimethylarginine (ADMA), pentraxin-3 (PTX-3) and high sensitivity C-reactive protein (hs-CRP) between patients with GS and controls and determine the correlation of unconjugated bilirubin (UCB) levels with these molecules as prognostic factors for vascular risk stratification and endothelial dysfunction.

Methods:

Forty two patients with GS and 37 age and sex matched control subjects were enrolled in this study. The diagnosis of GS was made by unconjugated hyperbilirubinemia (1 mg/dL or >17.1 μmol/L) on at least two occasions with normal values of other liver function tests, normal hepatic imaging, and absence of hemolysis.

Results:

Serum ADMA, PTX-3 and hs-CRP levels were significantly lower in GS than the healthy controls (p=0.037, p=0.025 and p=0.040, respectively). In correlation analysis, UCB was negatively correlated with ADMA, PTX-3 and hs-CRP (r=−0.239, p=0.034; r=−0.280, p=0.012 and r=−0.224, p=0.047, respectively).

Discussion and conclusion:

The present study showed for the first time that decreased levels of ADMA, PTX-3 and hs-CRP may prove the protective effects of hyperbilirubinemia on the endothelial dysfunction.

Özet

Amaç:

Gilbert Sendromu (GS), karaciğer hastalığı veya aşikar hemoliz belirti ve bulguları olmaksızın, azalmış hepatik glukuronidasyon aktivitesi ile ilişkili, indirekt hiperbilirubinemi ile karakterize benign bir durumdur. Bu çalışmada, GS olan hastalar ile kontrol grubundaki hastaların dolaşımdaki asimetrik dimetilarginin (ADMA), pentraksin-3 (PTX-3) ve yüksek duyarlıklı C-reaktif protein (hs-CRP) düzeylerini değerlendirmek ve vasküler risk sınıflandırması ve endotel disfonksiyonu için prognostik faktörler olarak bu moleküller ile indirekt bilirubin (İB) düzeyleri arasındaki korelasyonunu belirlemek amaçlanmıştır.

Yöntem ve Gereçler:

GS olan 42 hasta ve yaş ve cinsiyet eş değer olan 37 kontrol hastası çalışmaya dahil edilmiştir. GS tanısı, diger karaciğer fonksiyon testlerinin normal değerlerde tespit edildiği, karaciğer görüntülemesinin normal olduğu ve hemoliz yokluğunda gerçekleştirilen en az iki farklı ölçümde indirekt hiperbilirubinemi (1 mg/dL veya >17.1 μmol/L) varlığı ile konulmuştur.

Bulgular:

Serum ADMA, PTX-3 ve hs-CRP düzeyleri GS hastalarında sağlıklı kontrollere göre anlamlı derecede düşük bulunmuştur (sırasıyla; p=0.037; p=0.025 ve p=0.040). Korelasyon analizinde, İB’nin ADMA, PTX-3 ve hs-CRP ile negatif yönde korele olduğu tespit edilmiştir (sırasıyla; r=−0.239, p=0.034; r=−0.280, p=0.012 ve r=−0.224, p=0.047).

Tartışma ve Sonuç:

Bu çalışmada ilk kez ADMA, PTX-3 ve hs-CRP düzeylerindeki azalma ile hiperbilirubineminin endotel disfonksiyonu üzerine olan koruyucu etkileri ortaya konulmuştur.

Keywords: Gilbert’s syndrome; endothelial dysfunction; asymmetric dimethylarginine; pentraxin-3; high sensitivity C-reactive protein

Anahtar kelimeler: : Gilbert Sendromu; endotel disfonksiyonu; asimetrik dimetilarginin; pentraksin-3; yüksek duyarlıklı C-reaktif protein

References

  • 1.

    Gilbert A, Lereboullet P. La cholemie simple familiale. Sem Med 1901;21:241–3.Google Scholar

  • 2.

    Tapan S, Karadurmus N, Dogru T, Ercin CN, Tasci I, Bilgi C, et al. Decreased small dense LDL levels in Gilbert’s syndrome. Clin Biochem 2011;44:300–3.Google Scholar

  • 3.

    Hsieh TY, Shiu TY, Chu NF, Chao TY, Chu HC, Chang WK, et al. Rapid molecular diagnosis of the Gilbert’s syndrome-associated exon 1 mutation within the UGT1A1 gene. Genet Mol Res 2014;13:670–9.Google Scholar

  • 4.

    Sieg A, Arab L, Schlierf G, Stiehl A, Kommerell B. Prevalence of Gilbert’s syndrome in Germany. Dtsch Med Wochenschr 1987;112:1206–8.Google Scholar

  • 5.

    Vítek L, Kráslová I, Muchová L, Novotný L, Yamaguchi T. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J Gastroenterol Hepatol 2007;22:841–5.Google Scholar

  • 6.

    Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert’s syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008;199:390–6.Google Scholar

  • 7.

    Boon AC, Hawkins CL, Coombes JS, Wagner KH, Bulmer AC. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med 2015;86:259–68.Google Scholar

  • 8.

    Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J 2010;51:86–91.Google Scholar

  • 9.

    Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995;41:1504–8.Google Scholar

  • 10.

    Djousse L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87:1196–200.Google Scholar

  • 11.

    Gullu H, Erdogan D, Tok D, Topcu S, Caliskan M, Ulus T, et al. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 2005;25:2289–94.Google Scholar

  • 12.

    Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40:18–23.Google Scholar

  • 13.

    Antoniades C, Demosthenous M, Tousoulis D, Antonopoulos AS, Vlachopoulos C, Toutouza M, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011;58:93–8.Google Scholar

  • 14.

    Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273–83.Google Scholar

  • 15.

    Isıklar OO, Barutcuoglu B, Kabaroglu C, Mutaf I, Ozmen D, Bayındır O, et al. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases? Clin Biochem 2012;45:1325–30.Google Scholar

  • 16.

    Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008;28:1–13.Google Scholar

  • 17.

    Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006;45:326–30.Google Scholar

  • 18.

    Fazzini F, Peri G, Doni A, Dell’Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841–50.Google Scholar

  • 19.

    Jylhävä J, Haarala A, Kähönen M, Lehtimäki T, Jula A, Moilanen L, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011;164:211–7.Google Scholar

  • 20.

    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.Google Scholar

  • 21.

    Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation 2012;126:598–603.Google Scholar

  • 22.

    Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–26.Google Scholar

  • 23.

    Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009;386:338–44.Google Scholar

  • 24.

    Mazzone GL, Rigato I, Ostrow JD, Tiribelli C. Bilirubin effect on endothelial adhesion molecules expression is mediated by the NF-kB signaling pathway. BioSci Trends 2009;3:151–7.Google Scholar

  • 25.

    Kocaman SA, Sahinarslan A, Biberoglu G, Hasanoglu A, Akyel A, Timurkaynak T, et al. Asymmetric dimethylarginine and coronary collateral vessel development. Coron Artery Dis 2008;19:469–74.Google Scholar

  • 26.

    Kocaman SA. Asymmetric dimethylarginine, NO and collateral growth. Anadolu Kardiyol Derg 2009;9:417–20.Google Scholar

  • 27.

    Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161–7.Google Scholar

  • 28.

    Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48–55.Google Scholar

  • 29.

    Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10–4.Google Scholar

  • 30.

    Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009;29:594–9.Google Scholar

  • 31.

    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.Google Scholar

  • 32.

    Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009;120:699–708.Google Scholar

  • 33.

    Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092–5.Google Scholar

  • 34.

    Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010;11:328–34.Google Scholar

  • 35.

    Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005;25:155–60.Google Scholar

  • 36.

    Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima– media thickness in both men and women. Atherosclerosis 2006;184:431–7.Google Scholar

  • 37.

    Tapan S, Dogru T, Tasci I, Ercin CN, Ozgurtas T, Erbil MK. Soluble CD40 ligand and soluble P-selectin levels in Gilbert’s syndrome: a link to protection against atherosclerosis? Clin Biochem 2009;42:791–5.Google Scholar

  • 38.

    Vítek L, Jirsa M, Brodanová M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;160:449–56.Google Scholar

  • 39.

    Yoshino S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Oketani N, et al. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J Atheroscler Thromb 2011;18:403–12.Google Scholar

  • 40.

    Bhuiyan AR, Srinivasan SR, Chen W, Sultana A, Berenson GS. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism 2008;57:612–6.Google Scholar

  • 41.

    Boon AC, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner KH, et al. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 2012;52:2120–7.Google Scholar

  • 42.

    Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999 – 2006. J Clin Med Res 2010;2:201–6.Google Scholar

  • 43.

    Malhi H, Gores GJ. Mechanisms of Liver Injury. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff’s Diseases of the Liver. 9th Edition Lippincott, Philadelphia: Williams & Wilkins, 2003. pp. 231.Google Scholar

About the article

Received: 2015-12-11

Accepted: 2016-04-19

Published Online: 2016-10-14

Published in Print: 2016-12-01


Conflict of interest statement: Authors have no conflict of interest.


Citation Information: Turkish Journal of Biochemistry, Volume 41, Issue 6, Pages 451–458, ISSN (Online) 1303-829X, ISSN (Print) 0250-4685, DOI: https://doi.org/10.1515/tjb-2016-0150.

Export Citation

©2016 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in